Spero Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 1.06 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 61.73M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, man...